Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
Recorded changes
82,180 on record
Recorded policy changes, newest first| Recorded | Payer | Policy | Change |
|---|
| Sep 30, 2026 | Capital Blue Cross | Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Breast Cancer (Brca1, Brca2, Pik3ca, Ki-67, Ret, Braf, Esr1, Ntrk) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.393 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genotyping for 9p21 Single Nucleotide Polymorphism to Predict Risk of Cardiovascular Disease and Aneurysm (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.311 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genotype-Guided Warfarin Dosing (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.306 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genotype-Guided Tamoxifen Treatment (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.307 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing of CADASIL Syndrome (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.247 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.355 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Predisposition to Inherited Hypertrophic Cardiomyopathy (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.248 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Pathogenic FMR1 Variants (Including Fragile X Syndrome) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.276 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for PTEN Hamartoma Tumor Syndrome (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.255 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Neurofibromatosis (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.358 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Mitochondrial Disorders (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.273 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Marfan Syndrome, Thoracic Aortic Aneurysms and Dissections, and Related Disorders (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.331 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Macular Degeneration (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.260 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Lynch Syndrome and Inherited Colon Cancer Syndromes (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-5.013 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Lipoprotein(a) Variant(s) as a Decision Aid for Aspirin Treatment (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.310 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Limb Girdle Muscular Dystrophies (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.332 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Li-Fraumeni Syndrome (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.274 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Inherited Thrombophilia (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.253 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Idiopathic Dilated Cardiomyopathy (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.328 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Heterozygous Familial Hypercholesterolemia (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.363 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Hereditary Pancreatitis (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.318 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Hereditary Hemochromatosis (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.312 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Hereditary Hearing Loss (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.319 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Helicobacter Pylori Treatment (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.308 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Fanconi Anemia (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.362 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Familial Cutaneous Malignant Melanoma (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.246 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Facioscpulohumeral Muscular Dystrophy (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.321 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for FLT3, NPM1 and CEBPA Variants in Cytogenetically Normal Acute Myeloid Leukemia (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.357 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Epilepsy (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.262 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Duchenne and Becker Muscular Dystrophy (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.257 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Diagnosis and Management of Mental Health Conditions (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.264 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for DD, ID, Autism Spectrum Disorder and CA (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.242 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Cardiac Ion Channelopathies (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.233 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for CHARGE Syndrome (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.322 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Alzheimer Disease (Formerly Diagnostic Testing and Risk Assessment for Alzheimer Disease) (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.050 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Alpha-1 Antitrypsin Deficiency (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.251 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Testing for Alpha Thalassemia (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.320 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic Cancer Susceptibility Panels Using Next Generational Sequencing (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.325 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.280 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | General Approach to Genetic Testing (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.326 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | General Approach to Evaluating the Utility of Genetic Panels (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.323 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Gene Expression Profiling for Uveal Melanoma (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.360 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Gene Expression Profiling for Cutaneous Melanoma (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.396 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Gene Expression Profiling, Protein Biomarkers, and Multimodal Artificial Intelligence for Prostate Cancer Management (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.263 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Gene Expression Profile Testing and Circulating Tumor DNA testing for Predicting Recurrence in Colon Cancer (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.315 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Gene Expression Based Assays for Cancers of Unknown Primary (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.245 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Gastric Electrical StimulationPayerPolicy · CAPBLUE-MP-2.069 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Ganglion Impar BlockPayerPolicy · CAPBLUE-MP-2.378 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Experimental and Investigational ProceduresPayerPolicy · CAPBLUE-MP-4.002 | Metadata changed |
|---|
| Sep 30, 2026 | Capital Blue Cross | Evaluation of Biomarkers for Alzheimer's Disease (Retired 7/1/2026)PayerPolicy · CAPBLUE-MP-2.391 | Metadata changed |
|---|